Draft Note Guidance Investigation Bioavailability ...
INVESTIGATION OF BIOAVAILABILITY AND BIOEQUIVALENCE TABLE OF CONTENTS 1 INTRODUCTION 2 2 DEFINITIONS 3 2.1 Pharmaceutical equivalence 3 2.2 Pharmaceutical alternatives 3 2.3 Bioavailability 3 ... 24 This guideline should be read in conjunction with Directive 75-318/EEC, as amended, and
Download Draft Note Guidance Investigation Bioavailability ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Incident Reporting and Investigation Guidelines
healthandsafety.curtin.edu.auIncident Investigation Guideline.IIGGUI.V1.SM.NG.02122011.pdf Page 10 of 14 (Issued: Dec 2011) Health and Safety 7.3 COMPLETING THE RMSS INVESTIGATION WORKBENCH Event Investigation Quick Reference RMSS Event Manager The Event Investigation Quick Reference is designed to assist anyone new to using the RMSS software with the
ICH HARMONISED GUIDELINE
database.ich.orgdiseases or for modification of physiological function (see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 1.2 Adverse Event (AE) Any untoward medical occurrence in a patient or clinical investigation subject administered a
Contamination) Measure April 2011 National Environment of ...
nepc.gov.auSchedule B (1) - Guideline on Investigation Levels for Soil and Groundwater 3 1 Introduction The purpose of site assessment is to determine the human health and ecological risks associated with existing site contamination and to inform any remediation or management plan to make the site fit for the proposed land use.
Guideline on the investigation of drug interactions
www.ema.europa.euGuideline on the investigation of drug interactions CPMP/EWP/560/95/Rev. 1 Corr. 2** Page 5/59 This document provides recommendations on the pharmacokinetic and pharmacodynamic drug-drug interaction studies as well as food-drug interaction studies to be conducted includ ing advice on study design, presentation of study results and translation ...